In vivo treatment with PTL and TEM combinations results in decrease of tumor burden. Primary AML cells (AML1) were injected into sublethally irradiated mice. Three weeks after transplant, mice were either left untreated or treated with DMAPT (D) or TEM (T), alone or in combination for 3 weeks. DMAPT was administered at a dose of 100 mg/kg 3× daily. TEM was administered 3 times a week at 5 mg/kg. Mice were euthanatized and bone marrow was analyzed for percentage of human cells using anti-human CD45 antibody.